



Blake, Cassels & Graydon LLP
Barristers & Solicitors
Patent & Trade-mark Agents
595 Burrard Street, P.O. Box 49314
Suite 2600, Three Bentall Centre
Vancouver BC V7X 1L3 Canada
Tel: 604-631-3300 Fax: 604-631-3309

July 31, 2020

VIA SEDAR

Reference: 191509/3

British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission
Nova Scotia Securities Commission

Dear Sirs/Mesdames:

Re: NervGen Pharma Corp.(the “Company”) – Amended and Restated Prospectus Supplement dated July 31, 2020

We refer to the amended and restated prospectus supplement dated July 31, 2020 (the “**Amended and Restated Prospectus Supplement**”), amending and restating the prospectus supplement dated July 29, 2020. The Amended and Restated Prospectus Supplement is supplemental to the short form base shelf prospectus dated January 2, 2020 (the “**Base Shelf Prospectus**” and together with the Prospectus Supplements, the “**Prospectus**”) relating to an offering of common shares in the capital of the Company and common share purchase warrants of the Company.

We hereby consent to the reference to our firm name on the cover page and under the heading “*Legal Matters*” in the Amended and Restated Prospectus Supplement.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that are derived from our legal opinion referred to above or that are within our knowledge as a result of the services that we performed in connection with such opinion.

Yours truly,

(Signed) “*Blake, Cassels & Graydon LLP*”